Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $29000.0.

  • Intellia Therapeutics' Capital Expenditures fell 9773.26% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 6859.27%. This contributed to the annual value of $5.8 million for FY2024, which is 5868.43% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Capital Expenditures of $29000.0 as of Q3 2025, which was down 9773.26% from $239000.0 recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Capital Expenditures ranged from a high of $4.5 million in Q3 2021 and a low of $29000.0 during Q3 2025
  • For the 5-year period, Intellia Therapeutics' Capital Expenditures averaged around $2.5 million, with its median value being $2.5 million (2024).
  • In the last 5 years, Intellia Therapeutics' Capital Expenditures soared by 55014.33% in 2021 and then crashed by 9773.26% in 2025.
  • Intellia Therapeutics' Capital Expenditures (Quarter) stood at $2.9 million in 2021, then soared by 36.4% to $3.9 million in 2022, then plummeted by 61.15% to $1.5 million in 2023, then crashed by 35.46% to $981000.0 in 2024, then crashed by 97.04% to $29000.0 in 2025.
  • Its Capital Expenditures was $29000.0 in Q3 2025, compared to $239000.0 in Q2 2025 and $735000.0 in Q1 2025.